<DOC>
	<DOCNO>NCT00766363</DOCNO>
	<brief_summary>This study conduct determine safety , tolerability , pharmacokinetics ( PK ) three different dos investigational medication , EVP-6124 , individual mild moderate Alzheimer 's disease also take Alzheimer 's medication ( AChEI [ acetylcholinesterase inhibitor ] : either donepezil rivastigmine ) . In addition , PK AChEI medication assess . Cognitive function evaluate exploratory basis .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic Study EVP-6124 Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , Phase 1b safety study three dose level EVP-6124 subject mild moderate Alzheimer 's disease take AChEI medication ( donepezil rivastigmine ) . Study drug supply capsule orally administer daily total 28 day . Eligible subject admit inpatient study unit Day -2 ( two day first dose study drug administer ) remain confined inpatient study unit total five day . Starting Day 4 , subject continue study outpatient setting , study visit Days 7 , 14 , 21 , 28 . Safety assessment , PK sampling , cognitive testing perform inpatient study visit .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Nicotinic Agonists</mesh_term>
	<criteria>male postmenopausal surgically sterile female pt 5090 yr old , meet clinical criterion probable Alzheimer 's disease ( MiniMental State Examination 1826 ; Hachinski Ischemic Score â‰¤4 ) must take donepezil rivastigmine least 3 mo . Unstable medical condition clinically significant judgment investigator ; major organ system dysfunction Untreated hypothyroidism Insufficiently control diabetes mellitus Diagnosis major depression require antidepressant medication within last 5 year Stroke within 6 month screen , concomitant onset dementia Certain concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Cognition</keyword>
</DOC>